Study focuses in on potential cause of antipsychotic-induced diabetes

Drug News and Perspectives

Volumn 18, Issue 8, 2005, Pages 481-482

  O'Neill, Michael F ^a  

^a Eolas Biosciences Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; HISTAMINE H1 RECEPTOR; MUSCARINIC M3 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

CORRELATION ANALYSIS; DELUSION; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE METABOLISM; HALLUCINATION; HUMAN; INCIDENCE; LAW SUIT; OBESITY; PANCREAS ISLET CELL; PATHOGENESIS; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; URINE INCONTINENCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; RECEPTOR, MUSCARINIC M3; RECEPTORS, HISTAMINE H1; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 30744461128     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.8.944541     Document Type: Review

References (4)

1. Hoffman, D.C. and Donovan, H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 1995, 120(2): 128-33.
2. Pouzet, B., Mow, T., Kreilgaard, M. and Velschow, S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 2003, 75(1): 133-40.
3. Silvestre, J.S. and Prous, J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005, 27(5): 289-304.
4. Johnson, D.E., Yamazaki, H., Ward, K.M. et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005, 54(5): 1552-8.